Carboxyfullerene neuroprotection postinjury in Parkinsonian nonhuman primates
- 8 July 2014
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 76 (3) , 393-402
Abstract
Objective: We evaluated the efficacy of the potent antioxidant C3 to salvage nigrostriatal neuronal function after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) exposure in nonhuman primates. C3 is a first‐in‐class functionalized water‐soluble fullerene that reduces oxygen radical species associated with neurodegeneration in in vitro studies. However, C3 has not been evaluated as a neuroprotective agent in a Parkinson model in vivo.Methods: Macaque fascicularis monkeys were used in a double‐blind, placebo‐controlled study design. MPTP‐lesioned primates were given systemic C3 (n = 8) or placebo (n = 7) for 2 months starting 1 week after MPTP. Outcomes included in vivo behavioral measures of motor parkinsonism using a validated nonhuman primate rating scale, kinematic analyses of peak upper extremity velocity, positron emission tomography imaging of 6‐[18F]fluorodopa (FD; reflects dopa decarboxylase) and [11C]dihydrotetrabenazine (DTBZ; reflects vesicular monoamine transporter type 2), ex vivo quantification of striatal dopamine, and stereologic counts of tyrosine hydroxylase–immunostained neurons in substantia nigra.Results: After 2 months, C3‐treated monkeys had significantly improved parkinsonian motor ratings, greater striatal FD and DTBZ uptake, and higher striatal dopamine levels. None of the C3‐treated animals developed any toxicity.Interpretation: Systemic treatment with C3 reduced striatal injury and improved motor function despite administration after the MPTP injury process had begun. These data strongly support further development of C3 as a promising therapeutic agent for Parkinson disease. Ann Neurol 2014;76:393–402Keywords
Funding Information
- National Institutes of Health (NS039913)
- National Institutes of Health (NS05425)
- National Institutes of Health (AG033679)
- National Institutes of Health (R21AG030320)
- National Institutes of Health (NS37688)
- National Institutes of Health (NS058714)
- Larry L. Hillblom Foundation
- National Institutes of Health (NS075321)
- American Parkinson Disease Association
- Barnes-Jewish Hospital Foundation
- Greater St. Louis Chapter of the American Parkinson Disease Association
- McDonnell Center for Higher Brain Function
- Selma I. Hartke bequest
This publication has 32 references indexed in Scilit:
- Non-Motor Symptoms in Patients with Parkinson’s Disease – Correlations with Inflammatory Cytokines in SerumPLOS ONE, 2012
- Low nigrostriatal reserve for motor parkinsonism in nonhuman primatesExperimental Neurology, 2012
- No Differential Regulation of Dopamine Transporter (DAT) and Vesicular Monoamine Transporter 2 (VMAT2) Binding in a Primate Model of Parkinson DiseasePLOS ONE, 2012
- Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the diseaseBritish Journal of Pharmacology, 2011
- Oxidation of 3,4-Dihydroxyphenylacetaldehyde, a Toxic Dopaminergic Metabolite, to a Semiquinone Radical and an ortho-QuinoneJournal of Biological Chemistry, 2011
- Interleukin-6 Mediates the Increase in NADPH-Oxidase in the Ketamine Model of SchizophreniaThe Journal of Neuroscience, 2008
- Cerebral Mitochondrial Metabolism in Early Parkinson's DiseaseJournal of Cerebral Blood Flow & Metabolism, 2008
- Registration of [18F]FDG microPET and small-animal MRINuclear Medicine and Biology, 2005
- A biologically effective fullerene (C60) derivative with superoxide dismutase mimetic propertiesFree Radical Biology and Medicine, 2004
- Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. GeneralizationsJournal of Cerebral Blood Flow & Metabolism, 1985